COMPANY
Clinical Phase 1
Keywords: rare disease IDH-wildtype Glioblastoma Glioblastoma Glioblastoma Multiforme Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype GBM Astrocytoma IDH-Mutant Astrocytoma Anaplastic Astrocytoma Recurrent Anaplastic Astrocytoma
Location: Menlo Park, CA · source · Oct 12, 2026
Profile checked Oct 10, 2026
Timeline
- Trial start Phase 1: Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma source ↗
- Trial start Phase 3: Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients source ↗
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT05879367 | Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma | Phase 1 | Recruiting | Jul 24, 2023 | Jun 30, 2026 (estimated) |
| NCT02796261 | Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients | Phase 3 | Unknown status (ClinicalTrials.gov) | 2016-07 | 2023-06 (estimated) |
